Join us at European Society of Medical Oncology Congress

September 8–12, 2017, Madrid, Spain

Visit our booth #15 and see how next-generation sequencing (NGS) drives advances in precision oncology. You will be able to learn more about immuno-oncology and liquid biopsy testing in clinical research, and the first truly IVD NGS solution for NSCLC biomarker testing, or just how NGS works.

Join our satellite symposium: "Next-generation sequencing - driving precision oncology research"

  • Date: Sunday, September 10, 2017
  • Time: 13.00–14.30
  • Venue: Jerez Auditorium, Madrid, Spain
  • Chair: Prof. José Carlos Machado, Board of Directors member and Group Coordinator – Ipatimup, Porto, Portugal
Join our booth and see how you can help us to donate to a British cancer charity.
Title Speaker
Oncomine Knowledgebase Reporter - Processing the NGS data for you
Managing, and ultimately interpreting, data produced by NGS in oncology presents a challenge. In her talk Isabelle will share her experience with NGS analysis of FFPE solid tumour tissue using Ion Torrent™ Oncomine™ Focus Assay (52 target genes) and Ion Torrent™ Oncomine™ Knowledge Base Report software. The software processes the data down to only relevant variant result, linking it with to drug labels, treatment guidelines, and open clinical trials, enabling the laboratory to provide clear and useful report.


Issabelle-Soubeyran
Isabelle Soubeyran, MD, PhD

Head of the Molecular Pathology Unit, Bergonié Cancer Institute, Bordeaux, France
Read more

Advancing lung liquid biopsy research with NGS
Tumour-specific mutations in plasma can serve as biomarkers for tumour detection, monitoring tumour response to therapies, detecting residual disease, and enabling long-term follow-up. Dr Normanno will present the results of an international multi-centre study using a NGS liquid biopsy assay. He will also discuss how this new workflow may enable in the future better understanding of tumour evolution during treatment or how to use research findings to inform anticipatory second- or third-line therapy according to the molecular evolution of residual disease.

Dr. Nicola Normanno
Dr Nicolas Normanno, MD

Chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy
Read more

Immune profiling of genetic instability in colorectal cancer
Immunotherapy, based on immune checkpoint inhibitors, is being routinely used in several types of cancer, including melanoma and lung cancer. In other models, such as colorectal cancer, gastric cancer and bladder cancer, advanced stage clinical trials show very promising results. Although effective, not every patient benefits from this type of treatment. Response to immunotherapy is likely to be dependent on more variables than immune checkpoint proteins expression alone and multiple biomarker approach is likely going to be necessary to deliver truly personalised treatment solutions. Prof. Jose Carlos Machado will discuss other approaches how, using the newest next-generation sequencing (NGS) technologies, to study immune system response to cancer development and establish more efficient biomarkers and biomarker signatures.

Prof. Jose Carlos Machado
Prof. José Carlos Machado, PhD

Board of Directors member and Group Coordinator
Ipatimup
, Porto, Portugal
Read more

To learn more about ESMO 2017 Congress visit official page ›